Aim: To characterize the effects of a heavy increase in training stress followed by a reduced stress on fasting plasma leptin levels in highly trained male rowers. Methods: 12 rowers underwent a 3-week period of maximally increased training stress followed by a 2-week tapering period. Results: A mean 22% increase in training stress caused a significant decrease (by 8%) in the leptin concentrations. A further increase in training stress by 25% significantly reduced leptin further by 35%. A 1st tapering week, during which the training stress was rapidly reduced by approximately 50%, significantly increased the plasma leptin concentrations by 29%. Plasma leptin was significantly increased further (by 4%) during the 2nd tapering week. Conclusion: Leptin is sensitive to pronounced changes in training stress in highly trained male rowers.

1.
Campfield LA, Smith FJ, Guisez Y, Devos R, Burn P: Recombinant mouse OB protein: Evidence for a peripherial signal linking adiposity and central neural networks. Science 1995;269:546–549.
2.
Flier JS: What’s in a name? In search of leptin’s physiologic role. J Clin Endocrinol Metab 1998;83:1407–1413.
3.
Hickey MS, Calsbeck DJ: Plasma leptin and exercise: Recent findings. Sports Med 2001;31:583–589.
4.
Sudi K, Jürimäe J, Payerl D, Pihl E, Möller R, Tafeit E, Jürimäe T: Relationship between subcutaneous fatness and leptin in male athletes. Med Sci Sports Exerc 2001;33:1324–1329.
5.
Hickey MS, Houmard JA, Considine RV, Tyndall GL, Midgette JB, Gavigan KE, Weidner ML, McCammon ML, Israel RG, Caro JF: Gender-dependent effects of exercise training on serum leptin levels in humans. Am J Physiol 1997;272:E562–E566.
6.
Pasman WJ, Westerterp-Plantenga MS, Saris WH: The effect of exercise training on leptin levels in obese males. Am J Physiol 1998;37:E280–E286.
7.
Steinacker JM, Lormes W, Kellmann M, Liu Y, Reissnecker S, Opitz-Gress A, Baller B, Gunther K, Petersen KG, Kallus KW, Lehmann M, Altenburg D: Training of junior rowers before world championships: Effects on performance, mood state and selected hormonal and metabolic responses. J Sports Med Phys Fitness 2000;40:327–335.
8.
Steinacker JM: Physiological aspects of training in rowing. Int J Sports Med 1993;14(suppl):3–10.
9.
Kuipers H, Keizer HA: Overtraining in elite athletes: Review and directions for the future. Sports Med 1988;6:79–92.
10.
Noland RC, Baker JT, Boudreau SR, Kobe RW, Tanner CJ, Hickner RC, McCammon MR, Houmard JA: Effect of intense training on plasma leptin in male and female swimmers. Med Sci Sports Exerc 2001;33:227–231.
11.
Saad MF, Khan A, Sharma A, Michael R, Riad-Gabriel MG, Boyadjian R, Jinagouda SD, Steil GM, Kamdar V: Physiological insulinemia acutely modulates plasma leptin. Diabetes 1998;47:544–549.
12.
Thong FS, McLean C, Graham TE: Plasma leptin in female athletes: Relationship with body fat, reproductive, nutritional, and endocrine factors. J Appl Physiol 2000;88:2037–2044.
13.
Scriba D, Aprath-Husmann I, Blum WF, Hauner H: Catecholamines supress leptin release from in vitro differentiated subcutaneous human adipocytes in primary culture via beta1- and beta2-adrenergic receptors. Eur J Endocrinol 2000;143:439–445.
14.
Trayhurn P, Hoggard N, Mercer JG, Rayner DV: Leptin: Fundamental aspects. Int J Obes Relat Metab Disord 1999;23(suppl 1):22–28.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.